Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   Cannabis aandelen

Amerikaanse aandelen« Terug naar discussie overzicht

Cannabis aandelen

Volgen
8.267 Posts
Pagina: «« 1 ... 375 376 377 378 379 ... 414 »» | Laatste | Omlaag ↓
  4. [verwijderd] 7 mei 2020 17:56
    quote:

    G.dezwaluw schreef op 7 mei 2020 17:32:

    Aleafia gaat terug lekker vandaag
    www.marketwatch.com/press-release/ale...

    Aleafia Health Subsidiary Emblem Germany Submits EU-GMP Certification Application
    Published: May 7, 2020 at 9:03 a.m. ET

    TORONTO, May 07, May 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Emblem Germany cannabis distribution center to be completed later this month

    -- Experienced senior management team has led the buildout and operation of multiple EU-GMP certified facilities

    -- Cannabis production operations underway at Paris Facility expansion, three business days following granting of new licence

    Aleafia Health Inc.'s (TSX: ALEF, OTC: ALEAF) ("Aleafia Health" or the "Company") indirect subsidiary, Emblem Germany GmbH ("Emblem Germany"), has formally submitted its application to German regulators for EU Good Manufacturing Practices ("EU-GMP") certification.

    The Company's newly licensed Paris Facility has been purpose built to meet EU-GMP certification requirements, pharmaceutical-grade production's highest standard, and as a result, provides wide access to global markets. The application, if successful, would allow the Company's Paris Facility to produce and export EU-GMP certified cannabis products to the European Union.

    Cannabis production operations commenced on May 6, 2020 at the Paris Facility Phase II expansion, only three business days following receipt of the amended Health Canada licence.

    Aleafia Health indirectly owns 60 percent of Emblem Germany, by way of a joint-venture between Emblem and German pharmaceutical wholesaler and logistics company, Acnos Pharma GmbH ("Acnos"). It is difficult to ascertain the timeline for securing certification, but the Company intends to continue preparing for an eventual facility inspection.
  5. Rider 7 mei 2020 18:45
    quote:

    Osho schreef op 7 mei 2020 17:56:

    [...]

    www.marketwatch.com/press-release/ale...

    Aleafia Health Subsidiary Emblem Germany Submits EU-GMP Certification Application
    Published: May 7, 2020 at 9:03 a.m. ET

    TORONTO, May 07, May 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Emblem Germany cannabis distribution center to be completed later this month

    -- Experienced senior management team has led the buildout and operation of multiple EU-GMP certified facilities

    -- Cannabis production operations underway at Paris Facility expansion, three business days following granting of new licence

    Aleafia Health Inc.'s (TSX: ALEF, OTC: ALEAF) ("Aleafia Health" or the "Company") indirect subsidiary, Emblem Germany GmbH ("Emblem Germany"), has formally submitted its application to German regulators for EU Good Manufacturing Practices ("EU-GMP") certification.

    The Company's newly licensed Paris Facility has been purpose built to meet EU-GMP certification requirements, pharmaceutical-grade production's highest standard, and as a result, provides wide access to global markets. The application, if successful, would allow the Company's Paris Facility to produce and export EU-GMP certified cannabis products to the European Union.

    Cannabis production operations commenced on May 6, 2020 at the Paris Facility Phase II expansion, only three business days following receipt of the amended Health Canada licence.

    Aleafia Health indirectly owns 60 percent of Emblem Germany, by way of a joint-venture between Emblem and German pharmaceutical wholesaler and logistics company, Acnos Pharma GmbH ("Acnos"). It is difficult to ascertain the timeline for securing certification, but the Company intends to continue preparing for an eventual facility inspection.
    Die zijn goed bezig! Rustig groeien en rekening houden met hun kosten. Ze zijn door de weerstand zie ik op TA van Binck. Weerstand is 0.92 nu.
  6. Sub!et 7 mei 2020 19:27
    Investors Should Be Looking For Companies With Strong Balance Sheets During These Uncertain Times EDITORIAL May 4, 2020
    Aleafia Health is Fully Funded and Positioned to Record Strong Growth

    In our opinion, we believe that Aleafia Health (ALEF.TO) (ALEAF) is one of the most compelling opportunities from a valuation standpoint. Not only does the Canadian cannabis producer have a strong balance sheet (more than $40 million of cash) but it also has an attractive growth profile and is levered to some of the most profitable verticals of the cannabis value chain.

    During the most recent quarters, Aleafia Health has reported impressive growth on a number of levels and this is a trend that we expect to continue on a going forward basis. The company has been focused on growing its production footprint while substantially increasing the number of registered medical cannabis patients that it serves.

    One of the reasons we are excited about Aleafia Health is due to the cost-conscious approach that it has taken for growth. Unlike many of its peers, Aleafia Health did not expand to quickly or make massive acquisitions. The management team has been able to pinpoint assets that have improved the company’s leverage to the global cannabis market without overextending itself. When compared to many of its peers that completed massive acquisitions and expanded too quickly, we believe that Aleafia Health is well positioned to continue to increase market share.

    Another reason we are excited about Aleafia Health is related to the structure of the business. The company is comprised of divisions that support each other, and we are favorable on the amount of synergies that can be found between these assets. From cannabis clinics to telemedicine, Aleafia Health represents a well-rounded business that has substantial growth prospects. The operating structure makes Aleafia Health a multi-faceted growth opportunity and we are favorable on the direction the management team is bringing the business.

    technical420.com/cannabis-article/inv...
  8. Sub!et 8 mei 2020 06:09
    Mar. 15, 2020
    seekingalpha.com/article/4332017-now-...

    ****So, they are there, but particularly the company that I’m really interested in is called IPOT.

    RS: IPOT?

    OB: Yes. It's Isracann (OTCPK:ISCNF). It’s a company that actually comes from British Columbia. It’s the first pure play company to enter the landscape in Israel and they have a desire to export large amounts of medical cannabis to Europe at the time and also to balance the Israeli market where there is a deficit, particularly there is a need to import right now from Portugal, and so this company, IPOT, it’s on the CSE wants to take on the mantle of creating an incredible, incredibly large cultivation farm in Israel for export.

    RS: Interesting.

    OB: They’re really, really interesting because they're actually not from Israel and I appreciate the external influence into the landscape here because quite often Middle Eastern business is Middle Eastern business and it's good to get a Western sense or sentiment to balance out the non-transparentness.

    RS: And then in terms of Israel being a – you know it’s a leader in R&D of cannabis, are you bullish on other areas? Or are you looking at other areas? You know – I mean people have a whole host of things to say about South America. They’re also talking about Africa and there's different companies getting into different parts of the world. Do you see any part of the world as something that you think might be more successful than another?

    OB: I mean, I see the whole world as successful. I do see the regulators moving so slowly and I was originally going to invest in stocks in Colombia, but I realized that the roll-out is so slow and even Israel it's – everything is so slow. Even Germany, particularly Germany – it's such a – slow roll out in Germany, but the amount of people that are receiving cannabis for medical purposes is not so much and it’s like the same amount of people as New Jersey that are receiving. It was like 60,000 people in New Jersey receiving cannabis for medical reasons, and so, there's 60,000 in Germany and that's not enough to support a global market. But the future and the development that will happen is not overnight, you know, that's the problem. Everyone wants things to happen overnight, but if it did happen overnight, it will collapse overnight also.

  9. Sub!et 8 mei 2020 06:30
    $ALEF

    www.otcmarkets.com/stock/ALEAF/news/A...
    Aleafia Health Provides Corporate Update

    Press Release | 05/07/2020
    TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) is announcing that director Bill Stewart has indicated his intention to resign from the Company’s Board effective May 15 along with outgoing directors Julian Fantino and Raf Souccar.

    As previously announced, two new independent directors, Rhonda Lawson and Glenn Washer will be appointed to the Board on May 16. The new Board will be composed entirely of independent members, furthering the Company’s goal of enacting strong corporate governance and best practices.

    “On behalf of the Aleafia Health team, I’d like to thank Bill for his long-standing contributions to the Company. Like Julian and Raf, his distinguished record as a first responder, serving as Chief of Toronto’s Fire Services, has served the Company well since its founding,” said Aleafia Health CEO Geoffrey Benic.

    “It’s been a great pleasure to see Aleafia Health’s development from concept to a strong and thriving publicly traded company today. The vision articulated by founders Julian and Raf in its founding remains true today as we provide science-based medical cannabis care to a broad range of patients,” said Stewart. “I wish the board, management and entire team well and look forward to Aleafia Health’s bright future.”

    Upon Ms. Lawson and Mr. Washer’s appointment, the Board intends to update its board leadership including the election of a new Board Chair.

  11. [verwijderd] 8 mei 2020 16:39
    quote:

    G.dezwaluw schreef op 8 mei 2020 15:57:

    Mssn gaat Aleafia sneller terug op 1CAD zitten dan gedacht, hopelijk niet te snel
    Kan mij niet snel genoeg gaan. Productiekosten zijn toch zeer belangrijk gebleken. Ben nu vooral benieuwd hoeveel ze produceren en verkocht hebben.

    Het is ook geen kleine organisatie. Emblem + Aleafia (en van de weinige mergers waarvan toch nog vruchten geplukt kunnen worden). Ik zit aan 1.26 met bijna 2400 stuks.
  14. Sub!et 8 mei 2020 19:54
    quote:

    RW1963 schreef op 5 mei 2020 17:09:

    Een tijdje niet meer gekeken hier omdat ik flink baal van Aurora. Ik sta al op dik verlies. Komt dit ooit nog weer goed? Wat denken jullie.
    Aurora Cannabis will roll up its shares Monday in a reverse stock split — here’s what you need to know
    Published: May 8, 2020

    www.marketwatch.com/story/aurora-cann...
  17. Empros 8 mei 2020 23:55
    quote:

    Rider schreef op 8 mei 2020 23:35:

    [...]

    Waarom nu al verkopen? Koers kan nog veel verder stijgen of een groot bedrijf zoals canopy kan overnamebod doen.. Heb 38 000 stuks aan 0.91cad. Ik doe ze niet weg onder 1.2.
    Same here! Ik meen te herinneren dat we hier samen reeds lang deze stock hebben (sinds Emblem?) en verder laten opbouwen. Ondertussen mijn Alef aan CAD 0.60 voor 98.000 stuks en begint aardig aan te tikken. Ik verkoop de helft aan 1.20 (na de cijfers) en heb dan de andere helft gratis om na te sudderen richting CAD3 volgend jaar.:) Touch wood. Ik heb er alle vertrouwen in.
  18. G.dezwaluw 9 mei 2020 08:36
    quote:

    Rider schreef op 8 mei 2020 23:35:

    [...]

    Waarom nu al verkopen? Koers kan nog veel verder stijgen of een groot bedrijf zoals canopy kan overnamebod doen.. Heb 38 000 stuks aan 0.91cad. Ik doe ze niet weg onder 1.2.
    Omdat ik denk dat de koers gisteren al wat ging zakken (zoals gebleken) + maandag mssn ook nog wat zal zakken (nu hoop ik van niet), om dan zo terug wat meer aandeeltjes in te slaan
  19. Rider 9 mei 2020 09:22
    quote:

    Empros schreef op 8 mei 2020 23:55:

    [...]

    Same here! Ik meen te herinneren dat we hier samen reeds lang deze stock hebben (sinds Emblem?) en verder laten opbouwen. Ondertussen mijn Alef aan CAD 0.60 voor 98.000 stuks en begint aardig aan te tikken. Ik verkoop de helft aan 1.20 (na de cijfers) en heb dan de andere helft gratis om na te sudderen richting CAD3 volgend jaar.:) Touch wood. Ik heb er alle vertrouwen in.
    Klopt volledig! Ik zal het zelfde doen aan 1.2 met een deel winst nemen en groot pakket laten staan voor de lange termijn. Het blijft nog altijd een nieuwe markt die nog moet ontwikkelen. Veel bedrijven zullen failliet gaan maar Aleafia heeft voldoende cash waar ze goed met omgaan en kunnen overleven.
8.267 Posts
Pagina: «« 1 ... 375 376 377 378 379 ... 414 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,397 +0,10 +7,71%
BESI 120,700 +4,70 +4,05%
Pharming 0,718 +0,02 +2,65%
Kendrion 10,500 +0,26 +2,54%
ASR Nederland 46,110 +1,13 +2,51%
Aegon 6,206 +0,15 +2,41%
ADYEN NV 1.431,800 +30,00 +2,14%
FASTNED 21,250 +0,35 +1,67%
Nedap N.V. 53,800 +0,80 +1,51%
AALBERTS NV 36,960 +0,52 +1,43%
ASMI 519,600 +7,20 +1,41%
CTP 15,320 +0,18 +1,19%
Air France-KLM 7,338 +0,08 +1,16%
ALLFUNDS GROUP 5,715 +0,05 +0,97%
Avantium 2,080 +0,02 +0,97%
BAM 4,200 +0,04 +0,96%
Fugro 17,550 +0,16 +0,92%
ACOMO 17,600 +0,16 +0,92%
EXOR NV 94,550 +0,80 +0,85%
B&S Group SA 4,375 +0,04 +0,81%
Vopak 43,580 +0,34 +0,79%
ING 14,742 +0,10 +0,70%
Brunel 8,900 +0,06 +0,68%
AZERION 1,200 +0,01 +0,67%
ASML 682,400 +4,50 +0,66%
AMG Critical Materials N.V. 14,700 +0,09 +0,62%
ASCX 1.238,77 +6,92 +0,56%
Sligro 10,780 +0,06 +0,56%
Aperam 27,060 +0,14 +0,52%
TKH 31,020 +0,16 +0,52%
Flow Traders 20,960 +0,10 +0,48%
RANDSTAD NV 42,300 +0,20 +0,48%
SHELL PLC 31,180 +0,15 +0,47%
ABN AMRO BANK N.V. 14,710 +0,05 +0,34%
Ahold Delhaize 32,920 +0,11 +0,34%
Wereldhave 14,100 +0,04 +0,28%
Eurocommercial Properties 23,400 +0,05 +0,21%
ArcelorMittal 24,000 +0,05 +0,21%
RENEWI 9,730 +0,02 +0,21%
NSI 19,740 +0,04 +0,20%
AEX 891,63 +1,71 +0,19%
Basic-Fit 20,880 +0,04 +0,19%
SBM Offshore 17,130 +0,03 +0,18%
IMCD 143,200 +0,25 +0,17%
HEIJMANS KON 30,950 +0,05 +0,16%
Alfen N.V. 11,075 +0,01 +0,14%
Fagron 18,320 +0,02 +0,11%
Corbion 22,200 +0,02 +0,09%
RELX 45,260 +0,04 +0,09%
Akzo Nobel 58,140 +0,04 +0,07%
Accsys 0,577 0,00 0,00%
Van Lanschot Kempen NV 43,200 0,00 0,00%
WDP 20,680 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
SIGNIFY NV 20,560 -0,96 -4,46%
Galapagos 25,860 -0,44 -1,67%
THEON INTERNAT 11,120 -0,18 -1,59%
NX FILTRATION 4,055 -0,06 -1,34%
UMG 22,990 -0,30 -1,29%
Heineken 69,000 -0,88 -1,26%
INPOST 16,180 -0,18 -1,10%
OCI 11,005 -0,10 -0,95%
UNILEVER PLC 56,060 -0,50 -0,88%
DSM FIRMENICH AG 103,650 -0,75 -0,72%
KPN 3,640 -0,02 -0,68%
PostNL 1,021 -0,01 -0,68%
Vastned 23,150 -0,10 -0,43%
JUST EAT TAKEAWAY 15,175 -0,05 -0,36%
CM.COM 6,050 -0,02 -0,33%
NN Group 42,520 -0,11 -0,26%
Arcadis 63,600 -0,15 -0,24%
Philips Koninklijke 25,060 -0,05 -0,20%
Sif Holding 12,500 -0,02 -0,16%
ForFarmers 3,240 0,00 -0,15%
TomTom 4,944 -0,01 -0,12%
JDE PEET'S 18,850 -0,02 -0,11%
AMX 869,62 -0,54 -0,06%
Wolters Kluwer 161,250 -0,05 -0,03%
PROSUS 39,170 0,00 -0,01%
vlag naam koers verschil relatief verschil
AEX 891,55 +1,63 +0,18%
AEX GR 3.497,72 +7,15 +0,20%
Germany40^ 20.196,60 +179,85 +0,90%
FTSE 100 8.329,06 -30,35 -0,36%
EURO50 4.905,51 +24,54 +0,50%
US30^ 44.907,10 +203,10 +0,45%
Nasd100^ 21.348,80 +114,80 +0,54%
US500^ 6.063,80 +14,14 +0,23%
Japan225^ 39.560,70 +316,50 +0,81%
VD-NEW 14,23 -0,63 -4,24%
#/^ Index indications calculated real time, zie disclaimer